TAGRAXOFUSP-ERZS: 438 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
438
Total FAERS Reports
114 (26.0%)
Deaths Reported
116
Hospitalizations
438
As Primary/Secondary Suspect
25
Life-Threatening
8
Disabilities
Prescription
Status
FDA Application: 761116 ·
First Report: 20000209 · Latest Report: 20250915
What Are the Most Common TAGRAXOFUSP-ERZS Side Effects?
#1 Most Reported
Capillary leak syndrome
110 reports (25.1%)
#2 Most Reported
Pyrexia
45 reports (10.3%)
#3 Most Reported
Death
36 reports (8.2%)
All TAGRAXOFUSP-ERZS Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Capillary leak syndrome | 110 | 25.1% | 35 | 55 |
| Pyrexia | 45 | 10.3% | 10 | 17 |
| Death | 36 | 8.2% | 36 | 3 |
| Disease progression | 33 | 7.5% | 16 | 6 |
| Thrombocytopenia | 26 | 5.9% | 7 | 10 |
| Blood albumin decreased | 24 | 5.5% | 2 | 8 |
| Acute kidney injury | 23 | 5.3% | 8 | 11 |
| Off label use | 23 | 5.3% | 12 | 6 |
| Weight increased | 22 | 5.0% | 8 | 6 |
| Transaminases increased | 21 | 4.8% | 6 | 6 |
| Tumour lysis syndrome | 21 | 4.8% | 9 | 3 |
| Sepsis | 19 | 4.3% | 9 | 14 |
| Liver function test increased | 18 | 4.1% | 3 | 5 |
| Hypoalbuminaemia | 17 | 3.9% | 2 | 7 |
| Hypotension | 17 | 3.9% | 7 | 10 |
| Dyspnoea | 15 | 3.4% | 3 | 9 |
| Hepatic enzyme increased | 15 | 3.4% | 0 | 5 |
| Pneumonia | 15 | 3.4% | 5 | 7 |
| Fatigue | 14 | 3.2% | 2 | 4 |
| Neoplasm recurrence | 14 | 3.2% | 9 | 2 |
Who Reports TAGRAXOFUSP-ERZS Side Effects? Age & Gender Data
Gender: 22.8% female, 77.2% male. Average age: 65.9 years. Most reports from: US. View detailed demographics →
Is TAGRAXOFUSP-ERZS Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2000 | 1 | 0 | 0 |
| 2017 | 1 | 0 | 0 |
| 2019 | 42 | 6 | 15 |
| 2020 | 46 | 12 | 15 |
| 2021 | 32 | 12 | 9 |
| 2022 | 24 | 7 | 9 |
| 2023 | 31 | 7 | 16 |
| 2024 | 24 | 6 | 10 |
| 2025 | 6 | 2 | 3 |
What Is TAGRAXOFUSP-ERZS Used For?
| Indication | Reports |
|---|---|
| Blastic plasmacytoid dendritic cell neoplasia | 273 |
| Product used for unknown indication | 109 |
| Acute myeloid leukaemia | 30 |
TAGRAXOFUSP-ERZS vs Alternatives: Which Is Safer?
TAGRAXOFUSP-ERZS vs TAHOR
TAGRAXOFUSP-ERZS vs TALAZOPARIB
TAGRAXOFUSP-ERZS vs TALC
TAGRAXOFUSP-ERZS vs TALIGLUCERASE ALFA
TAGRAXOFUSP-ERZS vs TALIMOGENE LAHERPAREPVEC
TAGRAXOFUSP-ERZS vs TALQUETAMAB
TAGRAXOFUSP-ERZS vs TALQUETAMAB-TGVS
TAGRAXOFUSP-ERZS vs TAMIFLU
TAGRAXOFUSP-ERZS vs TAMOXIFEN
TAGRAXOFUSP-ERZS vs TAMSULOSIN
Official FDA Label for TAGRAXOFUSP-ERZS
Official prescribing information from the FDA-approved drug label.